Robust evidence from animal and cellular studies supports the anti-inflammatory and metabolic effects of EPO; however, clinical data on non-hematopoietic EPO analogs in patients with obesity and metabolic disorders remain limited. Here, EPO is linked to obesity due to melanocortin 4 receptor deficiency.